Medigen Biotechnology Corp. (TPEX:3176)
Taiwan · Delayed Price · Currency is TWD 30.70
+0.45 (1.49%)
Jul 17, 2025, 2:31 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
Generic Drug, Aesthetic Medicine Product and Dietary Supplement | 709.05M | Log In | Log In | Log In | Log In | Upgrade |
Generic Drug, Aesthetic Medicine Product and Dietary Supplement Growth | 16.91% | Log In | Log In | Log In | Log In | Upgrade |
New Drug and Vaccine Research and Development | 389.62M | Log In | Log In | Log In | Log In | Upgrade |
New Drug and Vaccine Research and Development Growth | 6.73% | Log In | Log In | Log In | Log In | Upgrade |
Nucleic Acid | 59.05M | Log In | Log In | Log In | Log In | Upgrade |
Nucleic Acid Growth | -29.53% | Log In | Log In | Log In | Log In | Upgrade |
Cytotherapy | - | Log In | Log In | Log In | Log In | Upgrade |
Cytotherapy Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Adjustment and Elimination | - | Log In | Log In | Log In | Log In | Upgrade |
Adjustment and Elimination Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
Taiwan | 1.15B | Log In | Log In | Log In | Log In | Upgrade |
Taiwan Growth | 14.03% | Log In | Log In | Log In | Log In | Upgrade |
China | 6.30M | Log In | Log In | Log In | Log In | Upgrade |
China Growth | -84.10% | Log In | Log In | Log In | Log In | Upgrade |
Other Countries | 4.96M | Log In | Log In | Log In | Log In | Upgrade |
Other Countries Growth | -54.82% | Log In | Log In | Log In | Log In | Upgrade |
Discontinued Operations | - | Log In | Log In | Log In | Log In | Upgrade |
Discontinued Operations Growth | - | Log In | Log In | Log In | Log In | Upgrade |